Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1819479 in healthy Japanese males
NCT05469646Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI1819479 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of patients treated who experience treatment-emergent adverse event assessed as drug-related up to 64 Days. Started Aug 2022; status: completed.
02
Drugs
BI1819479
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05469646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469646.